Clinical Trial Update: Clinical Value of 89Zr-trastuzumab PET [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the clinical value of 89Zr-trastuzumab PET imaging in metastatic breast cancer; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• 89Zr-trastuzumab (zirconium-89-labeled trastuzumab)

Snippet

Sponsor: University Medical Center Groningen | Conditions: Metastatic Breast Cancer | Phase 2 | Status: COMPLETED